

POSTER PRESENTATION



Acrolein: blocking antibody formation: pro tumor, anti-allergy

Franziska Roth-Walter^{1*}, Anna Willensdorfer¹, Caroline Stremnitzer², Cornelia Schultz², Susanne Diesner³, Krisztina Szalai¹, Judit Fazekas², Anna Moskovskich¹, Alina Neunkirchner⁴, Hanna Birnleitner¹, Erika Jensen-Jarolim¹, Erika Jensen-Jarolim¹

From 5th International Symposium on Molecular Allergology (ISMA 2013) Vienna, Austria. 6-7 December 2013

Background

Allergic sensitization has been linked to active and passive smoking in exposed individuals and even their pets. We here investigated the contribution of acrolein, a compound generated in large amounts during smoking, during nasal sensitization and – based on the surprising preliminary results – on tumor growth. As a model antigen we used KLH with or without acrolein.

Methods

BALB/c mice were nasally sensitized 5 times in biweekly intervals with KLH alone or with KLH in conjunction with acrolein. Airway hyperreactivity was was measured according to change of enhanced pause and KLH-specific anaphylactic reaction was monitored in vivo Levels of specific antibodies as well as cytokine profile of KLH-stimulated splenocytes were analyzed by ELISA. Further, mouse D2F2-tumor cells were grafted to the flanks and tumor growth monitored in mice previously exposed to acrolein or buffer.

Results

Nasal application of KLH as model antigen induced specific IgG1-, IgG2a-, IgA- and IgE-levels. The same mice secreted elevated levels of IL5, IL13, IL10 and IFN- γ . They showed increased airway-hyperreactivity and had a significant drop in body temperature upon allergen challenge. Pointing towards tolerance, and against our expectations, presence of acrolein in the KLH-antigen significantly reduced specific antibody-titers, resulted in lower splenocyte cytokine production and prevented

¹University of Veterinary Medicine, Messerli Research Institute, Comparative Medicine, Vienna, Austria

Full list of author information is available at the end of the article



© 2014 Roth-Walter et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

anaphylaxis. However, the impaired immune response simultaneously led to a significantly higher tumor growth in mice exposed to acrolein than in the control group.

Conclusion

Acrolein in smoke – best known for its carcinogenic effect - decreases the risk of sensitization towards a specific antigen by inhibiting immune activation. Our data further suggest that Acrolein via the same mechanism acts tumor promoting in smokers.

Authors' details

¹University of Veterinary Medicine, Messerli Research Institute, Comparative Medicine, Vienna, Austria. ²Medical University of Vienna, Department of Pathophysiology and Allergy Research, Vienna, Austria. ³Medical University of Vienna, Department of Pediatrics and Adolescent Medicine, Vienna, Austria. ⁴Medical University of Vienna, Institute of Immunology, Vienna, Austria.

Published: 17 March 2014

doi:10.1186/2045-7022-4-S2-P31

Cite this article as: Roth-Walter *et al.*: **Acrolein: blocking antibody formation: pro tumor, anti-allergy.** *Clinical and Translational Allergy* 2014 **4**(Suppl 2):P31.